


## (S)-UFR2709

<b>Cat. No.:</b>	HY-137231A
<b>CAS No.:</b>	1431628-22-6
<b>Molecular Formula:</b>	C <sub>13</sub> H <sub>17</sub> NO <sub>2</sub>
<b>Molecular Weight:</b>	219.28
<b>Target:</b>	nAChR
<b>Pathway:</b>	Membrane Transporter/Ion Channel; Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	(S)-UFR2709 is a competitive nAChR antagonist and displays higher affinity for $\alpha_4\beta_2$ nAChRs than for $\alpha_7$ nAChRs. (S)-UFR2709 decreases anxiety and reduces ethanol consumption and ethanol preference in alcohol-preferring rats. (S)-UFR2709 acts as an anxiolytic agent and can be used for the study of nicotine addiction <sup>[1][2]</sup> .								
<b>In Vitro</b>	Brain nicotinic acetylcholine receptors (nAChRs) is a heterogeneous family of pentameric acetylcholine-gated cation channels, which is a molecular target for the treatment of alcohol abuse and dependence <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
<b>In Vivo</b>	<p>(S)-UFR2709 (50-100 <math>\mu</math>g/ml; 3 min and then maintained for another 5 min in a holding tank before testing the swimming behaviour in the test tank for a period of 5 min) produces a decrease in the bottom dwelling for NTT test, and UFR2709 induces a significant and dose-dependent decrease in bottom dwelling time to 52.9 and 87.0 s, respectively at 50 and 100 <math>\mu</math>g/ml<sup>[2]</sup>.</p> <p>(S)-UFR2709 (50-100 <math>\mu</math>g/ml) decreases nicotine-evoked mRNA expression of <math>\alpha_4</math> nACh receptor subunit, but UFR2709 has less effect on <math>\alpha_4</math> nACh receptor subunit in the brain of adult zebrafish<sup>[2]</sup>.</p> <p>(S)-UFR2709 (intraperitoneal injection; 1-10 mg/kg; daily; 17 days) reduces ethanol consumption and ethanol preference and increased water consumption in a dose-dependent manner. The most effective dose of UFR2709 is 2.5 mg/kg, it induces a 56% reduction in alcohol consumption. (S)-UFR2709 does not affect the weight or locomotor activity of the rats<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>High-alcohol-drinking UChB rats<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg, 5 mg/kg, 2.5 mg/kg, or 1 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; 1-10 mg/kg; daily; 17 days</td> </tr> <tr> <td>Result:</td> <td>Did not affect the weight or locomotor activity and reduced ethanol consumption and preference.</td> </tr> </table>	Animal Model:	High-alcohol-drinking UChB rats <sup>[1]</sup>	Dosage:	10 mg/kg, 5 mg/kg, 2.5 mg/kg, or 1 mg/kg	Administration:	Intraperitoneal injection; 1-10 mg/kg; daily; 17 days	Result:	Did not affect the weight or locomotor activity and reduced ethanol consumption and preference.
Animal Model:	High-alcohol-drinking UChB rats <sup>[1]</sup>								
Dosage:	10 mg/kg, 5 mg/kg, 2.5 mg/kg, or 1 mg/kg								
Administration:	Intraperitoneal injection; 1-10 mg/kg; daily; 17 days								
Result:	Did not affect the weight or locomotor activity and reduced ethanol consumption and preference.								

### REFERENCES

[1]. Gabriel Quiroz, et al. UFR2709, a Nicotinic Acetylcholine Receptor Antagonist, Decreases Ethanol Intake in Alcohol-Preferring Rats. Front Pharmacol. 2019 Dec 3;10:1429.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA